Edition:
United States

Qiagen NV (QIA.DE)

QIA.DE on Xetra

27.58EUR
3:00am EST
Change (% chg)

€0.41 (+1.53%)
Prev Close
€27.17
Open
€27.34
Day's High
€27.58
Day's Low
€27.34
Volume
874
Avg. Vol
526,977
52-wk High
€31.52
52-wk Low
€25.41

Select another date:

Fri, Dec 15 2017

Qiagen to pay Oxford Immunotec $27.5 million to settle patent case

Qiagen NV said on Friday it had agreed to pay $27.5 million to resolve a lawsuit claiming that a tuberculosis blood test it produces infringes patents held by competitor Oxford Immunotec Global PLC.

BRIEF-Oxford Immunotec And Qiagen Reached A Settlement In Lawsuit

* OXFORD IMMUNOTEC GLOBAL - CO, QIAGEN REACHED A SETTLEMENT IN LAWSUIT IN U.S. COURT ALLEGING PATENT INFRINGEMENT IN RELATION TO QIAGEN'S PRODUCTS

BRIEF-Qiagen To Transfer U.S. Listing Of Global Shares To Nyse

* QIAGEN TO TRANSFER U.S. LISTING OF GLOBAL SHARES TO NYSE Source text for Eikon: Further company coverage:

As Brexit looms, UK pitches new industry plan, wins support from Merck, Qiagen

LONDON Britain pitched a new strategy for industry on Monday, pledging greater state intervention to tackle weak productivity and to help the world's sixth largest economy cope with the upheaval of leaving the European Union.

As Brexit looms, UK pitches new industry plan, wins support from Merck, Qiagen

LONDON Britain pitched a new strategy for industry on Monday, pledging greater state intervention to tackle weak productivity and to help the world's sixth largest economy cope with the upheaval of leaving the European Union.

UPDATE 2-As Brexit looms, UK pitches new industry plan, wins support from Merck, Qiagen

* Drug industry remains concerned about Brexit impact (Adds Prime Minister, Business Secretary comments, reaction)

BRIEF-Qiagen NV posts qtrly adjusted EPS $0.32‍​

* Qiagen NV - reaffirming 2017 adjusted EPS target of $1.25-1.27 cer before restructuring‍​

BRIEF-Qiagen, Centogene to collaborate in bioinformatics for genetic diseases

* Qiagen and Centogene to collaborate in bioinformatics for genetic diseases

BRIEF-Angle partners Qiagen in liquid biopsy portolio

* Partnership will seek to combine angle's parsortix system for harvesting circulating tumor cells with qiagen's liquid biopsy solution portfolio Source text for Eikon: Further company coverage: (Reporting By London Bureau)

BRIEF-Bookrunner says Qiagen transaction priced at 30 pct premium on upsized $400 mln issue size

* BOOKRUNNER SAYS TRANSACTION WILL PRICE AT 0.50% COUPON AND 30% PREMIUM ON AN UPSIZED $400M ISSUE SIZE

Select another date: